Welcome to our dedicated page for Omeros SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digesting 200+ pages of Omeros trial data, cash-runway tables, and scientific jargon can stall even seasoned analysts. From tracking complement-pathway breakthroughs to spotting dilution risks, Omeros SEC documents are both pivotal and complex. That’s why investors searching for “Omeros SEC filings explained simply” or “how to read an Omeros annual report 10-K simplified” land here first.
Stock Titan’s AI instantly translates every 10-K, 10-Q, 8-K, and Form 4 into clear takeaways. Wondering about “Omeros quarterly earnings report 10-Q filing” or need “Omeros earnings report filing analysis”? Our platform highlights trial milestone updates, R&D spend, and going-concern language in seconds. Real-time alerts flag “Omeros Form 4 insider transactions real-time” so you never miss executive stock moves, while our side-by-side comparisons reveal trends across periods.
Every filing type is covered and contextually linked to Omeros’ business:
- 10-K & 10-Q: Follow liquidity projections, pipeline costs, and safety data—perfect for “understanding Omeros SEC documents with AI”.
- 8-K: Immediate insight into clinical readouts and FDA feedback—search for “Omeros 8-K material events explained”.
- Form 4: Monitor “Omeros insider trading Form 4 transactions” and “Omeros executive stock transactions Form 4” the moment they post.
- DEF 14A: Explore “Omeros proxy statement executive compensation” without paging through dense tables.
Skip the manual hunt for disclosures. Our AI-powered summaries, expert commentary, and real-time feeds transform Omeros filings into actionable knowledge, letting you focus on valuation, not pagination.
Omeros (OMER) has entered into a registered direct offering of 5,365,853 common shares at $4.10, a 14% premium to the 24-Jul-25 close ($3.59). Gross proceeds total $22.0 million; after the 6% placement fee to D. Boral Capital ($1.32 million) and other expenses, net cash is expected at roughly $20.3 million.
The raise increases shares outstanding from 61.8 million to 67.1 million (≈8.7% dilution) and lifts available cash from ≈$26 million (18-Jul-25) to >$45 million, funding general corporate uses, clinical and pre-clinical pipeline work and working capital. Management retains broad spending discretion.
Key pipeline points: FDA’s BLA for lead MASP-2 antibody narsoplimab in TA-TMA now carries a 26-Dec-25 PDUFA date; EMA review is ongoing with an opinion expected mid-2026. The company is also advancing MASP-3 inhibitor zaltenibart (PNH, C3G) and PDE7 program OMS527 (cocaine use disorder). Omeros is negotiating a potential multi-billion-dollar asset deal that could retire its $67.1 million term loan and part of its 2026 notes.
Despite the premium pricing, the offer adds to a $(193 million) adjusted tangible book deficit and follows an auditor going-concern warning. Investors face immediate dilution of $7.15 per share (net tangible book value basis) and future overhang from 19.6 million outstanding options and convertible notes.
FAQ
What is the current stock price of Omeros (OMER)?
What is the market cap of Omeros (OMER)?
